ISRCTN27397017进行中（未招募）4 期
Multicenter, open-label, randomized controlled clinical trial of prevalent peritoneal dialysis (PD) patients using the Patient Mobile Application (PMA) versus a standard care group: A pilot study.
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 入组人数
- 168
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patient =18 and =85 years of age.
- •2. Being diagnosed with chronic kidney disease with renal failure.
- •3. Being a prevalent PD patient (having reached day 90 in a chronic PD program)
- •4. Having a smart phone (patient or caregiver) that meets the conditions for installing the application (App).
排除标准
- •1. A patient who does not provide informed consent to participate in the study.
- •2. If the patient is female, pregnancy status.
- •3. Patients with a prescription for peritoneal dialysis due to a non-renal cause (e.g., cardiorenal).
- •4. Patients with cirrhosis or hepatic cancer.
- •5. A patient who is currently participating or has participated in a clinical trial within the last 30 days.
- •6. Patients with a sensory or cognitive compromise that prevents adequate interaction with the mobile device app.
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to assess the prognostic repercussions of rosuvastatin treatment in patients discharged after hospitalization for COVID-19 Positive.EUCTR2020-001319-26-ESInstituto de Investigación Sanitaria Fundación Jiménez Díaz1,080
进行中（未招募）
不适用
Multicenter randomised clinical trial comparing the efficacy of the combination of colistin as monotherapy versus colistin plus meropenem for the treatment of bacteriemia and pneumonia due to extremely resistant.Bacteriemia and Pneumonia due to Pseudomonas aeruginosaEUCTR2013-005583-25-ESConsorci Parc de Salut Mar de Barcelona
进行中（未招募）
不适用
A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and with telbivudine monotherapy in treatment naïve patients with HBeAg-positive chronic hepatitis BTreatment of naïve patients with HBeAg-positive compensated chronic hepatitis BMedDRA version: 8.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2006-004003-18-NLovartis Pharma Services AG300
进行中（未招募）
不适用
A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine (LDT600) 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and with telbivudine monotherapy in treatment naïve patients with HBeAg-positive chronic hepatitis BTreatment of naïve patients with HBeAg-positive compensated chronic hepatitis BMedDRA version: 8.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2006-004003-18-DEovartis Pharma Services AG300
进行中（未招募）
不适用
A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and with telbivudine monotherapy in treatment naïve patients with HBeAg-positive chronic hepatitis BTreatment of naïve patients with HBeAg-positive compensated chronic hepatitis BMedDRA version: 8.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2006-004003-18-BEovartis Pharma Services AG300